Hide filtersShow filters × Close Bryan, Garnier & Co acts as Joint Financial Advisor to the shareholders of Evolucare, leading player in the digital transformation of French healthcare, on the sale of the company to GPI, tech leader company in IT solutions, healthcare and social services Bryan, Garnier & Co acts as Sole Financial Advisor to the shareholders of Driiveme, leading automotive digital logistic solution provider, on the sale of a minority stake of the Company to ISAI Gestion Bryan, Garnier & Co acts as Joint Global Coordinator & Joint Bookrunner on HydrogenPro’s NOK 126 million Follow-on Offering Bryan, Garnier & Co acts as Sole Financial Advisor to the shareholders of Eve Systems GmbH, a leading technology company offering energy-efficient smart home devices solutions, on its sale to ABB Ltd. Bryan, Garnier & Co acts as Sole Financial Advisor to Physidia and its shareholders, a leading European renal care medtech company providing home haemodialysis solutions, on the sale of a majority stake to Columna Capital Bryan, Garnier & Co acts as Joint Global Coordinator & Joint Bookrunner on Medincell’s EUR 25 million Follow-on Offering Bryan, Garnier & Co acts as Sole Financial Advisor to the Shareholders of Metaco on its sale to Ripple Labs Bryan, Garnier & Co acts as the sole financial advisor to the shareholders of Tinqin on their recent sale to be ys Bryan, Garnier & Co acted as Sole Financial Advisor to Amplexor Life Sciences and its shareholder Acolad on the sale of the company to ArisGlobal, a Group backed by Nordic Capital Bryan, Garnier & Co acts as Sole Financial Advisor to Brainwave GRC, a pioneer in the identity analytics industry, on its sale to Radiant Logic, a portfolio company of TA Associates Bryan, Garnier & Co acts as Sole Financial Advisor to the shareholders of Telops, a world leader in thermal IR & hyperspectral imaging systems, on its sale to Photonis, a global leader of technological solutions for defence and industrial markets, backed by HLD Bryan, Garnier & Co acts as Financial Advisor & Placement Agent on Abivax’s EUR 130 million Cross-over Financing
